BIOANALYTICAL SYSTEMS INC
10-K, EX-27, 2000-12-29
LABORATORY APPARATUS & FURNITURE
Previous: BIOANALYTICAL SYSTEMS INC, 10-K, EX-23, 2000-12-29
Next: MANAGERS FUNDS, DEF 14C, 2000-12-29



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
Bioanalytical  Systems, Inc. consolidated  financial statements contained in the
company's  annual  report  on Form  10-K and is  qualified  in its  entirety  by
reference to such financial statements.
</LEGEND>
<CIK>                         0000720154
<NAME>                        Bioanalytical Systems, Ltd.
<MULTIPLIER>                  1000

<S>                                                   <C>                          <C>
<PERIOD-TYPE>                                               3-MOS                         YEAR
<FISCAL-YEAR-END>                                     SEP-30-2000                  SEP-30-2000
<PERIOD-START>                                         JUL-1-2000                   OCT-1-1999
<PERIOD-END>                                          SEP-30-2000                  SEP-30-2000
<CASH>                                                        478                          478
<SECURITIES>                                                    0                            0
<RECEIVABLES>                                               3,128                        3,128
<ALLOWANCES>                                                    0                            0
<INVENTORY>                                                 2,235                        2,235
<CURRENT-ASSETS>                                            6,620                        6,620
<PP&E>                                                     18,913                       18,913
<DEPRECIATION>                                              5,538                        5,538
<TOTAL-ASSETS>                                             26,662                       26,662
<CURRENT-LIABILITIES>                                       5,689                        5,689
<BONDS>                                                         0                            0
                                           0                            0
                                                     0                            0
<COMMON>                                                    1,011                        1,011
<OTHER-SE>                                                 15,051                       15,051
<TOTAL-LIABILITY-AND-EQUITY>                               26,662                       26,662
<SALES>                                                     2,147                        8,224
<TOTAL-REVENUES>                                            5,235                       19,223
<CGS>                                                         817                        2,974
<TOTAL-COSTS>                                               3,199                       12,219
<OTHER-EXPENSES>                                            2,143                        8,196
<LOSS-PROVISION>                                                0                            0
<INTEREST-EXPENSE>                                           (177)                        (554)
<INCOME-PRETAX>                                              (370)                      (1,813)
<INCOME-TAX>                                                   75                         (431)
<INCOME-CONTINUING>                                          (444)                      (1,382)
<DISCONTINUED>                                                  0                            0
<EXTRAORDINARY>                                                 0                            0
<CHANGES>                                                       0                            0
<NET-INCOME>                                                 (444)                      (1,382)
<EPS-BASIC>                                                  (.10)                        (.30)
<EPS-DILUTED>                                                (.10)                        (.30)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission